Pricing pressure continues to dampen the US Joint Fluid market, which experienced a double-digit decline of -9.9% according to SmartTRAK's Financial Dashboard results. While the market continues to expand in terms of the number of patients treated, ASPs have steadily eroded over the past three quarters since the Anthem non-coverage decision kicked in earlier this year. Year-to-date, the US Joint Fluid market slowed significantly, posting negative growth according to SmartTRAK estimates...
- Market Highlights and Overview
- Decline in Single-Injection Market
- 3-Injection Market Competition
- 5-Injection Market
SmartTRAK reports that all major Joint Fluid segments were down for the quarter, with the exception of the 2-injection market...
*This article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.